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M O L E C U L A R  B I O L O G Y
Functional coordination of BET family proteins 
underlies altered transcription associated with  
memory impairment in fragile X syndrome
Seung-Kyoon Kim1,2†, Xihui Liu2†‡, Jongmin Park1, Dahun Um1, Gokhul Kilaru2,  
Cheng-Ming Chiang3, Mingon Kang4, Kimberly M. Huber2, Keunsoo Kang5*, Tae-Kyung Kim1,2*§
Bromodomain and extraterminal proteins (BET) are epigenetic readers that play critical roles in gene regulation. 
Pharmacologic inhibition of the bromodomain present in all BET family members is a promising therapeutic strat-
egy for various diseases, but its impact on individual family members has not been well understood. Using a 
transcriptional induction paradigm in neurons, we have systematically demonstrated that three major BET family 
proteins (BRD2/3/4) participated in transcription with different recruitment kinetics, interdependency, and sensi-
tivity to a bromodomain inhibitor, JQ1. In a mouse model of fragile X syndrome (FXS), BRD2/3 and BRD4 showed 
oppositely altered expression and chromatin binding, correlating with transcriptional dysregulation. Acute inhi-
bition of CBP/p300 histone acetyltransferase (HAT) activity restored the altered binding patterns of BRD2 and 
BRD4 and rescued memory impairment in FXS. Our study emphasizes the importance of understanding the BET 
coordination controlled by a balanced action between HATs with different substrate specificity.
INTRODUCTION
Bromodomain and extraterminal (BET) proteins are epigenetic 
readers that share two conserved bromodomains and one extrater-
minal (ET) domain (1, 2). Among the BET family members, BRD2, 
BRD3, and BRD4 are ubiquitously expressed, but bromodomain 
testis-specific (BRDT) expression is limited to testis and oocytes (2). 
As epigenetic readers, BET proteins play a key role in gene tran-
scription through their interactions with chromatin and various 
transcription regulators (3–5). Being the most extensively studied 
family member, BRD4 mediates transcriptional responses by recruit-
ing several transcriptional regulators, including Mediator complex 
and positive transcription elongation factor b (P-TEFb) to the chro-
matin regions near the cis-regulatory regions such as promoters and 
enhancers (1, 6–8). The chromatin occupancy patterns of BRD4 is 
largely correlated with histone acetylation, suggesting the importance 
of the bromodomain-dependent recruitment mechanism, but evidence 
also supports that BRD4 recruitment could be mediated by direct 
interactions with various transcriptional regulators (e.g., P-TEFb, 
Myc/Max, and C/EBP and C/EBP) in either a bromodomain- 
dependent or bromodomain-independent manner (9–11).
Pharmacologic inhibition of BET protein function has been a 
promising therapeutic strategy for several diseases including can-
cers (4, 12–16), inflammation (17), and heart failure (18). To date, 
all small-molecule inhibitors of BET proteins including JQ1 com-
monly target the bromodomain binding pocket (13, 15, 17, 19), but 
the majority of studies have suggested that dysregulation of BRD4 
function is the primary effect of pharmacologic BET inhibition 
(5, 7, 11, 14–16, 18–20). JQ1 exhibits similar affinities to all major 
BET proteins (12, 13, 15, 17, 19), which suggests that in principle, 
JQ1-mediated inhibition could affect the bromodomain-dependent 
function of any BET family protein that shares the conserved bro-
modomains. The ubiquitously expressed BET proteins may work 
redundantly and/or coordinately as they exhibit overlapping genomic- 
binding profiles at active genes (12, 21) and associate with many 
common transcriptional regulators (8, 13, 22). On the other hand, 
several lines of evidence also point to their nonredundant or se-
lective roles in various biological pathways (3, 23–28). Distinctive 
functionality of BET family proteins might be mediated by different 
binding preference to the acetylated residues (15, 29, 30) and addi-
tional domains that affect their chromatin binding (10, 31, 32), dif-
ferences in interaction partners (8, 13, 22), and the regulatory 
capacity for higher-order chromatin architecture (24). Nonetheless, 
the functional distinctions among different BET family members at 
the molecular level are still poorly understood. This subject would 
be important for the accurate evaluation of the therapeutic benefits 
of currently available BET inhibitors as well as the development of 
more selective drugs that might benefit clinical interventions in a 
range of diseases.
Recent studies demonstrated that BET proteins are also impor-
tant for brain function and behavior. JQ1 blocks BRD4 function in 
neurons, resulting in impairment of transcriptional responses and 
various forms of learning and memory as well as long-term potentia-
tion (LTP) (33, 34). However, the therapeutic effects of BET inhibi-
tion have been somewhat incongruous. While treatment of wild-type 
(WT) mice with a brain-penetrable inhibitor, I-BET858, impairs 
neuronal gene expression programs and promotes the development 
of autism-like behaviors (35), JQ1 improves memory performance of 
WT mice in another study (36). In a fragile X mental retardation 1 
(Fmr1) knockout (KO) mouse, a model of autism spectrum disorder, 
fragile X syndrome (FXS), the level of BRD4 protein is elevated in 
the brain with widespread changes in chromatin regulation and 
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aberrant gene expression (37). JQ1 treatment alleviates FXS-related 
symptoms. JQ1 also ameliorates Alzheimer’s disease phenotypes 
in two different mouse models, but its effect in learning and mem-
ory deficits are varied (36, 38). In the case of a mouse model for 
Huntington’s disease (HD), JQ1 exacerbates the dysregulation of 
HD-related symptoms while enhancing motor performance in WT 
mice (39). Although these studies illustrate the functional relevance of 
BET inhibition to brain function and related diseases, the molecular 
changes of individual BET family members caused by small-molecule 
BET inhibition in the brain have not been investigated.
Sensory experience–evoked neuronal activity critically underlies 
brain development and function by inducing transcription from a 
specific set of genes called activity-induced genes. Activity-dependent 
gene expression is necessary for the long-lasting form of synaptic 
plasticity, which is generally considered as the cellular correlate for 
cognitive behaviors (40). Transcriptional response to neuronal ac-
tivity occurs in waves such that a distinctive set of genes is induced 
at different time windows following evoked activity. Immediately 
early genes such as Arc and Fos belong to the first responder group 
that is rapidly induced by neuronal activity, and their induction is 
critical for subsequent gene expression and behavior such as learn-
ing and memory. Disruption of activity-dependent gene expression 
programs has been linked to various brain disorders including au-
tism. Here, we dissect the functions of all three major BET family 
proteins, BRD2/3/4 in activity-dependent gene expression and long- 
term memory (LTM). We found that all three BET family proteins 
participated in activity-dependent gene expression. Despite signifi-
cant overlaps between their binding sites, individual BET family 
members exhibited notable differences in the sensitivity to inhibi-
tion of the BET bromodomain and CBP/p300 histone acetyltrans-
ferase (HAT) activity, recruitment kinetics, and protein-protein 
interactions. All three BET proteins are also involved in LTM and 
pathological aspects of FXS. Notably, our study uncovered that a 
small-molecule inhibitor of CBP/p300 HAT activity, C646, altered 
the chromatin binding patterns of BRD2/3/4 in a manner that can 
correct the abnormal BET occupancy patterns caused by Fmr1 loss 
of function. Together, our data indicate that BET family proteins do 
not simply act in redundancy, but instead, they coordinate with 
each other in a hierarchical manner during activity-dependent gene 
induction, and disruption of the coordinated BET network could 
contribute to the development of FXS.
RESULTS
BET inhibition affects neuronal activity–induced gene 
expression
To assess the effect of BET inhibition during activity-induced gene 
expression, primary cultures of mouse cortical neurons were pre-
treated with either +JQ1 (500 nM; BET bromodomain inhibitor) or 
−JQ1 (500 nM; stereoisomer of +JQ1, which has no significant in-
teraction with any BET) for 5 min and then membrane-depolarized 
by KCl to trigger activity-dependent transcription. mRNA sequenc-
ing (mRNA-seq) libraries were prepared from total RNAs collected 
at 1 and 3 hours following depolarization to examine the effect of 
JQ1 during the early stage of activity-induced transcription (Fig. 1A 
and fig. S1A). DESeq2 was used to identify differentially expressed 
genes (DEGs) between the conditions [+JQ1 versus −JQ1 at a 
matched time point (unstimulated, 1 hour, or 3 hours), fold change 
(FC)  >  1.5, and false discovery rate (FDR)  <  0.05]. The analysis 
found that 328 (758 transcripts) and 140 (303 transcripts) genes 
were reproducibly down-regulated (JQ1-down) and up-regulated 
(JQ1-up) by +JQ1 treatment, respectively (Fig. 1, A to C; fig. S1, B 
and C; and table S1). Other than these DEGs, acute BET inhibition 
had little impact on global transcriptome profiles of all expressed 
transcripts (Fig. 1A, right). About half of the JQ1–down-regulated 
genes were overlapped with KCl depolarization–induced genes 
(KCl-up), suggesting that BET proteins are functionally involved in 
activity-induced transcription (Fig. 1D and fig. S1D). Consistent 
with recently shown effect of JQ1 on fear memory (33), several 
learning and memory-related genes, such as Arc, Fosl2, Crem, and 
Bdnf, were included in the JQ1-down gene group (Fig. 1B and fig. 
S1B). Gene ontology (GO) analysis indicates that JQ1-down genes 
are significantly associated with gene transcription (Fig. 1, E and F). 
This result is consistent with the previously known fact that most 
immediate early genes (IEGs) encode transcription factors (TFs) 
that function in the subsequent wave of gene induction (40). JQ1-
up genes show fewer overlaps with KCl-up genes (33 of 140 genes) 
(Fig. 1D) and no significant GO enrichment for any biological pro-
cess or molecular function (Fig. 1G). Several memory-related genes 
present in JQ1-down or JQ1-up genes were further validated by 
real- time quantitative polymerase chain reaction (RT-qPCR) fol-
lowing JQ1 treatment in neurons (fig. S1E). Therefore, the primary 
function of BET proteins might be to promote activity-dependent 
gene expression.
To further validate that JQ1’s effect on gene expression is medi-
ated by BET family proteins, we knocked down all three BET pro-
teins and examined the transcriptome-wide changes by mRNA-seq 
(fig. S1F). A larger number of genes were affected by triple (BRD2/3/4) 
knockdown (KD) than JQ1. This could indicate that BET proteins 
function in transcription through both bromodomain-dependent and 
bromodomain-independent pathways as previously suggested (9–11). 
It could also reflect the difference in the duration of BET inhibition. 
JQ1 was added only 5 min before the KCl stimulation to minimize its 
secondary effect, whereas triple KD had to be performed for 3 days to 
ensure sufficient KD of all BET family proteins, during which any in-
direct changes in transcriptome could accumulate in addition to the 
changes occurred at direct BET protein target genes. Nonetheless, we 
observed that most of JQ1-down genes show a trend toward a decrease 
in transcription upon triple KD. Several memory-related genes (Fosl2, 
Crem, Arc, Bdnf, and Nr4a2) present in JQ1-down genes were further 
validated by RT-qPCR following the triple KD in neurons (fig. S1G). 
Therefore, JQ1-mediated changes in gene transcription most likely 
occur by alteration in BET protein functions.
We next examined the role of each BET family protein in activity- 
dependent gene transcription. BRD2/3/4 were known to be ubiquitously 
expressed (2, 12, 21), and we further confirmed their coexistence in 
the mouse cortex at a single-cell level by analyzing publicly available 
single-cell transcriptome data (fig. S2A and table S2). BRDT was 
known to be testis specific, and we also confirmed its extremely low 
RNA level in mouse cortical neurons (fig. S2B). We then performed 
short hairpin RNA (shRNA)–mediated KD of individual BET fam-
ily proteins to examine their unique and/or redundant functions. In 
this experiment, we performed global run-on sequencing (GRO-
seq) following each KD or triple KD (Fig. 1H) to gain a better sensi-
tivity and accuracy in assessing the impact of BET protein KD in 
RNA polymerase II (Pol II) transcriptional activity. For the KCl-up 
or JQ1-down genes that we identified from mRNA-seq, KD of each 
BET family protein had differential effects in transcription (Fig. 1, 
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I to K; fig. S2, C to F; and table S3). BRD2 KD caused the most sig-
nificant decreases in transcription. Single KD of BRD3 and BRD4 
had a little and moderate effect, respectively. The most marked effect 
of BRD2 single KD was unexpected since BRD4 dysregulation is 
widely believed to be responsible for JQ1-mediated inhibition (14–16). 
The overlap among individual KD-regulated genes (Fig. 1I and fig. 
S2C) further suggests that BET family proteins could work redun-
dantly or distinctively depending on the context of the target genes.
Fig. 1. BET proteins are functionally important for activity-induced transcription. (A) Cumulative plots showing the differences in expression levels (RPKM) of KCl- 
induced and all expressed transcripts between +JQ1- and −JQ1-treated neurons. (P values were from Kolmogorov-Smirnov test). (B) Scatterplots showing the reads per 
kilobase per million mapped reads (RPKM) values of JQ1-down or JQ1-up regulated transcripts in unstimulated and KCl-depolarized neurons (all dots). Red dots, KCl–
up-regulated transcripts; blue dots, the genes of our interest. (C) Violin plots showing RPKM (log2) changes of JQ1-down transcripts in different conditions. (P values were 
from two-tailed unpaired t test with Welch’s correction). (D) Venn diagram showing the overlaps between different gene groups. (E) Heatmap showing the expression FC 
of JQ1-down or JQ1-up genes at KCl depolarized over unstimulated condition. (F and G) Top five GO terms of JQ1-down (F) and JQ1-up genes (G). Dashed lines, P = 0.01. 
ER, endoplasmic reticulum. (H) Western blotting data showing the KD efficiency of BET proteins. MW, molecular weight; IB, immunoblotting. (I) Venn diagram showing the 
overlaps between the genes down-regulated by each shBET- and JQ1-down genes. (P values were from hypergeometric test). (J and K) Violin plots showing RPKM (log2) of 
KCl-up/JQ1-down (J) and all genes (K) in unstimulated or KCl-stimulated conditions. (P values were from two-tailed unpaired t test with Welch’s correction).
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JQ1 differentially affects BET protein bindings during 
activity-dependent transcription
JQ1 has similar affinities to the bromodomains of BET family pro-
teins in vitro (4, 12). To examine the sensitivity of individual BET 
family proteins to JQ1 in an in vivo context, we analyzed the global 
binding profiles of BRD2/3/4  in neurons treated with or without 
JQ1 during activity-induced transcription. Chromatin immunopre-
cipitation (ChIP)–qPCR results showed that all three BET proteins 
are inducibly recruited to the promoters of several JQ1-down genes 
(Fosl2, Crem, and Arc) after depolarization, which was significantly 
blocked by JQ1 pretreatment (fig. S3A). JQ1 is a specific BET bromo-
domain inhibitor with no detectable binding to other bromodomain- 
containing proteins (e.g., CBP) in the range of dose used in most 
studies (15). To further examine this issue, we performed ChIP- qPCR 
analyses of CREB-binding protein (CBP) and E1A binding protein 
p300 (p300) and found no difference in their binding at several 
target promoters (fig. S3B). Therefore, ChIP sequencing (ChIP-seq) 
was carried out in neurons harvested at 30 min after depolarization 
(fig. S3, C and D). The peak annotation revealed that BRD2/3/4 are 
prominently enriched at the promoters and within the gene body 
(>86% of the total peaks) (Fig. 2A). A stark contrast was that a small 
portion (26 to 30%) of BET protein binding sites are located to the 
enhancer regions (Fig. 2, A and B). We also observed extensive 
overlaps between the binding sites of these factors, implying possible 
functional redundancies (Fig. 2C). To examine whether JQ1 sensi-
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Fig. 2. JQ1 differentially affects the recruitment of BET proteins. (A) Pie chart showing the genomic distribution of BET proteins. (30-min KCl-depolarized neurons). 
3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region; CDS, coding sequence; TTS, transcription termination site; BRD, bromodomain-containing protein. (B) Pie chart 
showing the fraction of BET protein master peaks present at enhancers and non-enhancers. (C) Proportional Venn diagram showing the overlap between each BET protein 
master peak. (D) Violin plots showing the FC of the ChIP-seq mater peaks (tag counts in +JQ1 over −JQ1) present in the gene body and up to 5-kb upstream regions of annotated 
genes. The genes were categorized on the basis of the co-occupancy of BET proteins. (P values were from Kruskal-Wallis test). (E) ChIP-seq read density plots of each 
BET protein at the transcription start sites (TSSs) or the enhancer centers of different gene categories. (−JQ1 and +JQ1 conditions). (F) ChIP-seq read density profiles 
of Pol II, H3K27ac, CBP, and each BET protein around the TSSs. (G) Heatmaps showing the ChIP-seq signals for each BET protein around the TSSs of BET-bound genes.
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categorized the binding peaks of all three BET proteins based on 
their overlaps with one another (e.g., BRD2 peak alone, BRD2/3-co-
bound, BRD2/3/4-cobound, etc.) and then examined any differenc-
es in JQ1 sensitivity between the categories (Fig. 2D and fig. S4A). 
In all categories, BRD2 was more vulnerable to JQ1 than BRD3 and 
BRD4. BRD4 showed the least sensitivity to JQ1, and even more, 
about one-third of BRD4 peaks were actually increased by JQ1. We 
further observed that JQ1 sensitivity is generally correlated with the 
degree of overlaps among BET protein peaks. Those peaks over-
lapped by all three BET proteins were most sensitive to JQ1 
(Fig. 2D). The peak annotation showed that BET proteins bind to 
the promoters and/or the coding regions of 11,214 genes. RNA se-
quencing (RNA-seq) analysis estimated that 12,723 genes are tran-
scriptionally active, producing RNA reads higher than the background, 
and more than two-thirds of them were directly bound by BET pro-
teins (fig. S4, B and C). Therefore, BET proteins bind to most of 
transcriptionally expressed genes in various combinations. Notably, 
the majority of BRD2 peaks coexist with BRD3 at the promoters 
(95.03% of total BRD2 peaks), suggesting their close relationship 
(Fig. 2C and fig. S4A). In contrast, BRD3 and BRD4 not only work 
together with the other family members but also regulate some genes 
independently of other family members.
The JQ1 sensitivity patterns at the promoters or enhancers of 
different gene categories were similar to those shown by the peak-
based analysis (Fig. 2E). BRD2 binding levels were most markedly 
decreased by JQ1 across all categories, whereas BRD4 binding was 
least affected or even higher with JQ1 (Fig. 2E and fig. S4A). Despite 
the large number of genes occupied by BET family proteins, only 
328 genes were significantly down-regulated by JQ1 (Figs. 1, B and E, 
and 2E). For these genes, all three BET members show significantly 
reduced binding at the promoters upon JQ1 treatment, suggesting 
that the bromodomain-dependent recruitment of BET proteins is 
critical for these selected genes. We also noted that the binding lev-
els of BRD3 and BRD4 were relatively lower at the promoters of 
JQ1-down genes than those at other gene groups (Fig. 2E; note that 
y-axis values at different gene categories differ). Therefore, the 
prominent binding of BRD2 at this gene group that becomes more 
effectively inhibited by JQ1 might be, in part, responsible for selec-
tive transcriptional down-regulation. The binding levels of BET pro-
teins at the promoters of JQ1-up genes are either slightly reduced 
(BRD2) or not reduced at all (BRD3/4) by JQ1 (Fig. 2E), suggesting 
that increased transcription by JQ1 at these genes is most likely due 
to a secondary effect. While different JQ1 sensitivity of individual 
BET family proteins suggests that each BET family member differ-
entially uses the bromodomain-dependent function, other factors 
such as potential differences in the chromatin on-off rate might also 
contribute to the observed differences. Prolonged JQ1 treatment 
(overnight) significantly reduced all three BET proteins’ binding to 
the promoters where BRD2 was only affected by the short-term 
treatment (fig. S4, D and E).
Together with peak-based analysis, these results suggest that BRD2 
recruitment to the chromatin depends heavily on its bromodomain- 
mediated interaction with acetylated proteins. In contrast, a large 
portion of BRD3 and BRD4 recruitment might be made through a 
bromodomain-independent mechanism (e.g., ET domain– mediated 
interactions with transcription regulators). This idea is further sup-
ported by the aggregate plots (Fig. 2F). The average density of BRD2 
ChIP-seq reads surrounding the transcription start sites (TSSs) of all 
annotated genes exhibits a distinct bimodal shape that coincides 
with positioned nucleosomes flanking the TSSs determined by the 
peak densities of H3K27ac, which suggests that BRD2 is recruited 
to acetylated nucleosomes. In contrast, both BRD3 and BRD4 show 
a single average peak that is situated within the nucleosome- free 
regions (NFRs) where transcription complexes are assembled. Thus, 
various transcriptional regulators present in the NFRs most likely 
play a role in the recruitment of BRD3/4. Since the binding of 
most BRD3 and BRD4 was not affected by JQ1, bromodomain- 
independent recruitment might be a dominating mechanism in this 
case. These aggregated peak patterns could also be seen by heat-
maps (Fig. 2G). This model is based on the average peak intensities 
at all annotated gene promoters, thus we also anticipate that a dif-
ferent mode of recruitment could occur for each BET protein de-
pending on the gene context. Nonetheless, it is conceivable that 
BET protein recruitment to the target genes is a coordinated pro-
cess involving both bromodomain-dependent and bromodomain- 
independent interactions. Together, the chromatin occupancy profiles 
support the findings from the transcriptome analysis that BET fam-
ily proteins can function together or independently depending on 
the gene context. For shared target genes, individual BET proteins 
are recruited by distinctive mechanisms, during which BRD2 and 
BRD3 more closely coordinate with each other than with BRD4.
Enhancer-bound BET proteins are more sensitive to JQ1
Previous studies suggested that the transcriptional impact of BET 
inhibition occurs at a rather small set of genes (2, 3). Such a selective 
effect was attributed to the preferential disruption of BRD4 binding 
at the enhancers (9, 27). We next analyzed how JQ1 affected the 
binding of BRD2/3/4 at the enhancers. A total of 12,449 enhancers 
were identified on the basis of the H3K27ac-enriched peaks. We 
then split them into super-enhancer (SE; 667) and typical-enhancer 
(TE; 11,782) groups, as previously reported (Fig. 3A) (9). The aver-
age enrichment level of BET proteins at all SEs was much higher 
than that at all TEs (Fig. 3B). However, when the enhancers were 
further divided by the combinatorial binding patterns of BET fami-
ly members, we found that TE-bound BET proteins show a higher 
enrichment than SE-bound BET proteins in all subgroups (Fig. 3C 
and fig. S4, F and G). We infer that in addition to SEs, those subsets 
of TEs strongly bound by BET proteins might be actively engaged in 
activity-induced transcriptional control. In all cases, the enhancer- 
bound BET proteins are more vulnerable to JQ1 treatment compared 
to the promoter-bound BET proteins, although BRD2 still showed 
the highest sensitivity to JQ1 among all BET family members (Figs. 2E 
and 3, B and C, and fig. S4, F and G). This observation is consist-
ent with previous reports demonstrating that the bromodomain- 
dependent recruitment of BET proteins is a prominent feature of 
the enhancers (9).
We next examined how many of the JQ1-down genes resulted 
from reduced BET protein activity at the enhancers. We identified 
928 and 2955 genes as SE- and TE-regulated genes, respectively, 
based on the ±50-kb window centered on BET-bound enhancers 
(Fig. 3, D and E, and fig. S4, H to J). GO analysis indicates that BET-
bound SEs are significantly associated with gene transcription ac-
tivities, neuron related or differentiation/development related, and 
TE-regulated genes are significantly associated with gene transcrip-
tion activities, RNA processing, or protein modification (table S4). 
About one-third of the JQ1-down genes (121 of 328 genes) belong 
to the enhancer-regulated genes. We did not see any bias in the over-
lap of JQ1-down genes with the SE- or TE-regulated gene group 
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(Fig. 3E and fig. S4J), suggesting that both SE- and TE-associated 
BET proteins contribute to the regulation of target genes. All of 
those enhancer-associated and JQ1-down genes also showed signif-
icant levels of BET protein binding at their promoters (Figs. 2E and 
3D and fig. S4, H and I). One hundred twenty-nine genes (39.3%) of 
the remaining JQ1-down genes had BET protein bindings only at 
the promoter regions, leaving only 78 genes (23.7% of JQ1-down 
genes) as BET protein independent (Fig. 3G and fig. S4L). There-
fore, about two-thirds of JQ1-down genes are considered as direct 
targets of BET proteins acting on the enhancers and/or the promot-
ers. We next examined transcriptional changes associated with dif-
ferent enhancer subgroups. As expected, a triple KD of BRD2/3/4 
led to a significant decrease in transcription of JQ1-down genes 
(Fig. 3F and fig. S4K). Although only a small portion of the 
enhancer-regulated genes (121 of 3579) was JQ1-down, the remaining 
enhancer-regulated genes (3458 genes of 3579 genes) became sig-
nificantly down-regulated by a triple KD of BRD2/3/4 regardless of 
their associations with SEs or TEs (Fig. 3H and fig. S4M). This pat-
tern of transcriptional effect was also observed when the enhancers 
were separately analyzed for the SE and TE groups (Fig. 3F and fig. 
S4K). Given that the enhancer-bound BET proteins are significant-
ly disrupted by JQ1 treatment, those enhancer-regulated genes that 
are insensitive to JQ1 treatment (Fig. 3, F and H) could indicate that 
promoter-associated BET proteins in this category function through 
bromodomain-independent mechanisms. Together, our dissection 
defines that BET proteins regulate transcription through their com-
binatorial actions at selected promoters and enhancers without any 
biased usage between SEs and TEs. Although more sensitive pertur-
bation of BET function at the selected enhancers could account for 
JQ1-mediated transcriptional down-regulation, a similar portion of 
JQ1-down genes showed promoter-dependent activity of BET proteins.
Sequential recruitment of BET proteins
To examine the mechanism of BET protein coordination, we next 
investigated the recruitment kinetics for each family member by 
performing ChIP-seq in neurons at different time points following 
membrane depolarization. Neuronal activity was first suppressed 
by tetrodotoxin (TTX; quiescent neurons; unstimulated; 0 min); 
then, neurons were synchronously depolarized for various dura-
tions (10, 30, 60, and 120 min of KCl treatment). All BET members 
show strong activity-induced binding at cis-regulatory regions con-
sistent with BET protein involvement in activity-dependent gene 
expression (Fig. 4, A to C, and fig. S5, A to C). Induced binding of 
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Fig. 3. Comparison of BET protein binding profiles between SEs and TEs. (A) Ranking of super-enhancer (ROSE) analysis using H3K27ac ChIP-seq data that determines 
SEs. (B and C) ChIP-seq read density plots at all or BRD2/3/4-cobound SEs or TEs. (D) ChIP-seq read density plots of BET proteins near the TSSs of BET-bound genes that 
are located within ±50 kb from the SE or TE (SE/TE-regulated genes). (E) Venn diagram showing the overlap between JQ1-down and BRD2/3/4-bound SE/TE-regulated 
genes. (P values were from hypergeometric test). (F) Violin plots showing the RPKM-FC (log2) values of the genes in each category shown in (E) after BRD2/3/4 triple KD 
(top) or JQ1 treatment (bottom). (G) Venn diagram showing the overlaps among JQ1-down/BET-bound genes, JQ1-down/BRD-unbound genes and BRD2/3/4-bound 
SE/TE-regulated genes. (P values were from hypergeometric test). (H) Violin plots showing the RPKM-FC (log2) of the genes in each category shown in (G) after BRD2/3/4 
triple KD (top) or JQ1 treatment (bottom). (P values were from Mann-Whitney U test).
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Fig. 4. BET proteins are recruited to the cis-regulatory regions with different kinetics. (A) ChIP-seq tracks showing the binding kinetics of each BET protein at the 
Fosl2 gene locus after KCl depolarization. (B) The average ChIP-seq signals of BET proteins at different time points following KCl depolarization are shown at the TSS re-
gions of KCl-up/JQ1-down genes. (C) The average ChIP-seq signals at BRD2/3/4-cobound SEs or TEs following KCl depolarization. (D) ChIP-seq tracks showing the binding 
kinetics of each BET protein at the Fosl2 gene locus after BDNF stimulation (10 ng/ml). (E) The average ChIP-seq signals of BET proteins at different time points following 
BDNF stimulation are shown at the TSS regions of KCl-up/JQ1-down genes. (F) The average ChIP-seq signals at BRD2/3/4-cobound SEs or TEs following BDNF stimulation.
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(10 min), followed by BRD4 binding at 30 min. Notable was that 
unlike the other members, a substantial level of BRD3 binding was 
present in quiescent neurons (0 min), with more BRD3 recruited 
together with BRD2 immediately following the activity increase. 
Binding of BRD2 and BRD3 persists until the measured duration 
(2 hours), whereas BRD4 begins to decline after 30 min of peak, 
showing a more dynamic induction pattern. These results suggest a 
temporally differentiated action of each BET member during activity- 
induced transcription in neurons. This pattern of distinctive recruit-
ments also occurs in response to a different stimulus, brain-derived 
neurotrophic factor (BDNF), which induces genes that are crucial 
for neuronal function and survival (35). Similar to the KCl-induced 
responses, BET proteins showed distinct temporal binding patterns 
upon BDNF treatment (Fig. 4, D to F, and fig. S5, D to F). But in this 
case, the level of prebound BRD3 before BDNF treatment was lower 
than that in the TTX-mediated quiescent condition in membrane de-
polarization experiments (compare Fig. 4, B and E, at 0 min). The 
difference might be due to ongoing spontaneous neuronal firing activ-
ity in the BDNF experiment that prevents the stable association of 
BRD3 before BDNF addition. Temporally defined binding patterns of 
BET proteins are consistent with the model that BET family proteins 
functionally coordinate with each other during transcriptional acti-
vation. In light of the transcriptional activation process, the observed 
sequential recruitment could imply the distinctive roles of individual 
BET family members in gene activation. For example, BRD3 might 
have a role in the suppression of activity-dependent genes before an 
activation signal and then becomes a part of the activator complex 
together with BRD2 that functions to initiate the transcriptional activa-
tion process. Delayed association of BRD4 suggests its role in a later 
stage of transcription such as Pol II elongation (7, 9), as the BRD4- 
binding peaks coincide with the first wave of IEG transcription.
Chromatin recruitment of BRD2 and BRD3 occurs 
in an interdependent manner
The recruitment kinetics analysis described above indicates that 
BRD2 and BRD3 might work closely with one another, especially 
during the early stage of transcriptional activation. To gain addi-
tional molecular insight into the coordination between BET family 
members, we performed a single KD of each family member and 
examined its impact on chromatin occupancy of the other family 
members. KD of either BRD2 or BRD3 alone markedly decreased 
the chromatin occupancy of the other (Fig. 5, A and B, and fig. S6A). 
The BRD4 binding level was also reduced but to a lesser degree. 
BRD4 KD did not affect the binding levels of BRD2 and BRD3. This 
result indicates that BRD2 and BRD3 coordinate with each other 
for their recruitment to the cis-regulatory regions. Consistently, co- 
immunoprecipitation (co-IP) assay using nuclear lysates prepared 
from neurons with and without membrane depolarization showed 
that BRD2 and BRD3, but not BRD4, were efficiently pulled down 
by reciprocal IPs (Fig. 5, C and D). We next analyzed protein com-
plexes associated with each BET family member by rapid immuno-
precipitation mass spectrometry of endogenous proteins (RIME), 
which is a formaldehyde cross-linking–based method that analyzes 
endogenous protein complexes, especially chromatin and TF com-
plexes by mass spectrometry (MS) (41). A total of 781 proteins were 
identified as BET-associated proteins (FDR < 0.05). As expected for 
the epigenetic reader, all histone subunits were significantly en-
riched in the BET-immunoprecipitated fractions (Fig. 5E). In addi-
tion, BET complexes contain a number of chromatin-associated 
proteins that were previously shown to interact with BET proteins 
such as barrier-to-autointegration factor (BAF) and nucleosome re-
modeling and deacetylase (NuRD) complexes (8, 22, 24, 42, 43). The 
majority of the BET-associated proteins were commonly identified 
in individual family members’ IP fractions, indicating that all three 
family members jointly participate in the formation of protein com-
plexes. However, each BET family member exhibits rather distinctive 
dynamic ranges of interactions with associated proteins in an activity- 
dependent manner (Fig. 5F and fig. S6, B to D). BRD4 showed the 
highest dynamic range of interactions with associated proteins 
whereas BRD2-associated complexes were relatively stable with ac-
tivity change. GO analysis revealed that a significant portion of BET- 
interacting proteins functions in RNA processing, translation, and 
metabolism (table S5, A to C), suggesting broad functions of BET 
proteins beyond the regulation of chromatin and transcription. We 
then selected the proteins with chromatin- and transcription- related 
functions and examined their association patterns with each BET 
family member in response to KCl depolarization (Fig. 5G, fig. S6E, 
and table S5, D to K). Most of the proteins were associated with 
more than one BET family members, although neuronal activity 
alters their association with each BET member differently. BRD3 
appears to be the common component in most of the protein com-
plexes in these categories. These results demonstrate that the chromatin 
regulation is highly coordinated by all three BET family members with 
distinctive functional contributions in an activity-dependent manner. 
Together with the kinetics analysis (Fig. 4), we suggest a mechanistic 
model that upon KCl depolarization, BRD2 and BRD3 are rapidly 
recruited to the chromatin in an interdependent manner. The sub-
sequent binding of BRD4 completes the formation of the functional 
transcription complexes required for productive transcriptional 
induction. In this regard, individual BET proteins might function 
at different stages of transcription such that the main role of BRD2/3 
might be to remodel the promoters and enhancers to activate the tran-
scriptional initiation process, whereas BRD4 is primarily involved in 
transcription elongation. This model is consistent with previously 
shown BRD4 function in transcription elongation (7, 9).
Individual BET proteins differentially affect 
memory formation
BET inhibition was shown to improve pathological conditions of 
autism and neurodegeneration by altering gene expression programs 
in the brain (35–37, 39). Consistently, our JQ1-down gene group 
also includes several learning and memory-related genes (e.g., Fosl2 
and Bdnf) (Fig. 1B). We next examined the functional involvement 
of each BET family protein in the formation of LTM, which has not 
been demonstrated in previous studies (33, 34). We first performed 
a contextual fear memory test with JQ1 or vehicle (dimethyl sulfox-
ide) injected 15 min before conditioning to determine the effect of 
an acute BET inhibition in LTM. Because of the acute immobility 
effect of +JQ1 at high doses, we optimized the dose (12.5 mg/kg) 
that does not affect the mobility of mice (fig. S7A). Under this con-
dition, JQ1-injected mice exhibited a level of freezing similar to that 
of the vehicle-treated mice during fear conditioning. However, their 
freezing rates upon reexposure to the context in the following day 
(24 hours) were significantly lower than the vehicle control group, 
indicating impairment in LTM consolidation (Fig. 6A). Since JQ1 
was injected only once at 15  min before contextual conditioning 
with a short half-life (~1 hour), this result suggests that BET family 
proteins play a role in memory formation by participating in the 
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Q8BTS0 Ddx5 52 69.2 BRD234
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D3YY44 Dpf1 1 45.3
Q9Z0H3 Smarcb1 3 44.1
Q61687 Atrx 1 278.4 X X BRD34
P60122 Ruvbl1 9 50.2 BRD234
Q9WTM5 Ruvbl2 1 51.1
Q9CU62 Smc1a 4 143.1 BRD234
Q9CW03 Smc3 2 141.5 X X BRD23
























775 proteins with FDR > 5%
BRD4
643 proteins with FDR > 5%
C
























































      -BRD4
IB: Anti
      -BRD2
IB: Anti















Q6PDY0 Ccdc85b 1 22.1 2/3/4 up BRD
   2/3/4Q8C854 Myef2 19 63.3
Q8CBB6 Hist1h2bq 71 14.9
Q6GSS7 Hist2h2aa1 27 14.1
P62806 H4c1 56 11.4
Q8VH51 Rbm39 6 59.4
E9PYL1 Chd5 1 222.5
Q80ZM5 H1f10 1 20.1
Q9QZQ8 Macroh2a1 3 39.7
Q08943 Ssrp1 2 80.8
O88712 Ctbp1 5 47.7 23 up & 4 dn
P60122 Ruvbl1 9 50.2
O54879 Hmgb3 1 23
B2RU90 Prdm8 5 71.7
Q9DCT8 Crip2 3 22.7 2 dn & 34 up
Q9JIF0 Prmt1 8 42.4
Q60972 Rbbp4 7 47.6
Q64511 Top2b 8 181.8
Q62318 Trim28 10 88.8
Q8K4B0 Mta1 3 80.7 24 dn & 3 up
P43277 H1.3 9 22.1
A0A1W2P768 H3c14 3 20.2 23 up BRD2/3
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P56546 Ctbp2 4 48.9
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O35129 Phb2 4 33.3
Q5SUS9 Ewsr1 3 69
Q9R190 Mta2 2 75 2 up & 3 dn
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Q8CCK0 Macroh2a2 5 40.1
Q61687 Atrx 1 278.4 X 34 up BRD3/4
P97863 Nfib 2 63.5 X
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D3Z357 Nsd3 5 161.5 X
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Q9JJ28 Flii 2 144.7 X X 3 up BRD3
Q62432 Smad2 1 52.2 X
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Fig. 5. Recruitment of BRD2 and BRD3 is interdependent. (A) Representative ChIP-seq tracks at the Fosl2 gene locus. ChIP-seq was performed in neurons after KD of 
each BET family member or Scrambled control (Scr). (B) The average occupancy profiles of BET proteins around the TSSs of KCl-up/JQ1-down genes after KD of each BET 
protein. (C) Co-IP experiment with nuclear extracts prepared from unstimulated or KCl-depolarized neurons. (D) Quantification of co-IP Western blot using ImageJ. Bar 
graphs show means ± SEM. (P values were from two-tailed unpaired t test with Welch’s correction). (E) BET interacting proteins determined by RIME in histones and chro-
matin remodeling complex categories. (F) The FC in abundance (log2) of BRD2-, BRD3-, or BRD4-associated proteins between unstimulated and KCl-stimulated conditions. 
The proteins are ranked by the log2 FC values (KCl 30 min/Unst.). (P values were from Mann-Whitney U test). (G) BET-associated proteins with chromatin-related functions. 
The genes are grouped on the basis of the direction of abundance changes in each BET protein complex. The color scale indicates the FC of abundance (KCl 30 min/Unst.). 
(P values were from two-tailed unpaired t test with Welch’s correction).
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rapid induction of gene expression during the early stage of memory 
formation in vivo. We also measured RNA levels of several memory 
genes in the cortex and hippocampus isolated from fear-conditioned 
mice with and without JQ1 treatment and found that JQ1 inhibited 
induction of Fosl2, Crem, and Bdnf (isoforms 1 and 4) in at least one 
brain region (Fig. 6B and fig. S7B). Therefore, the behavioral im-
pairment caused by JQ1 is associated with transcriptional changes 
in some of the key memory genes in vivo.
We next examined the functional contributions of individual 
BET family members in memory formation in vivo. We stereotaxi-
cally injected AAVs (adeno-associated viruses)–expressing shRNAs 
against each BET family members or all three members into the 
hippocampus. Two weeks later, AAV-injected mice were subjected to 
contextual fear conditioning. The KD efficiency was validated at the 
protein level in the hippocampal tissues isolated from individual 
KDs (Fig. 6C). Triple KD of BET proteins showed the biggest effect 
in LTM (Fig. 6D and fig. S7C). However, KD of each BET family 
member alone was also sufficient to impair LTM albeit all weaker 
than the triple KD. The extent of LTM impairment caused by each 
KD was different such that BRD2 KD caused the most severe im-
pairment, followed by KD of BRD4 and then BRD3. The observed 
differential impact in LTM mirrors the extent of gene expression 
changes caused by KD of each BET family members in neurons 
(Fig. 1J). These results collectively demonstrate that each BET protein 
differentially contributes to LTM by regulating activity-dependent 
gene expression.
BET proteins are differentially impaired in the FXS
A previous study demonstrated that an Fmr1-encoded protein 
(FMRP) deficiency–caused increase in BRD4 protein level underlies 
Fig. 6. JQ1 and KD of BET family proteins impair LTM. (A) Long-term fear memory test. Schematics of conditioning procedure (top) and freezing behavior results 
during the initial training and test period are shown (bottom, n = 11 or 13 for vehicle or JQ1). (B) RT-qPCR data from cortical tissues extracted from mice treated as indi-
cated (n = 6). Three different alternative transcripts of the Bdnf gene were included (Bdnf_t: common exon, Bdnf_1: exon 1, Bdnf_4: exon 4). Bar graphs show means ± SEM. 
(P values were from two-tailed unpaired t test with Welch’s correction). (C) Western blotting of each BET protein from the hippocampal tissues extracted from AAV-infected 
regions. (D) Long-term fear memory test with mice treated with Scr, single, or triple KD of BET proteins (n = 9). (P values were from one-way analysis of variance with 
Tukey’s posttest). N.S., not significant.
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the pathogenesis of FXS, and JQ1-mediated inhibition of BRD4 al-
leviates several phenotypes associated with FXS (37). To gain addi-
tional molecular insight into the BET protein function in FXS, we 
investigated all three BET proteins in Fmr1 KO mice. We first com-
pared the protein expression levels of BRD2, BRD3, and BRD4 in 
the cortices isolated from WT littermate controls and Fmr1 KO at 
postnatal day (P) 0, 20, and 60. Expression of all three BET proteins 
was gradually decreased in WT (fig. S8A). Consistent with a previ-
ous report (37), the level of BRD4 protein was elevated in Fmr1 KO 
compared to WT, but the level of the difference between WT and 
Fmr1 KO varied with the developmental stage such that only P20 
showed a significant difference (Fig. 7A). Unexpectedly, we also 
found that BRD2/3 expression was significantly decreased in Fmr1 
KO at P20 and P60 (Fig. 7, A and B, and fig. S8B). These changes in 
protein expression levels appear to occur at the translation level, as 
no significant changes in mRNA levels were detected in the previ-
ous report (37). We then performed ChIP-seq for each BET family 
member in cortical tissues isolated at P60 to see whether such changes 
in expression also affected the chromatin occupancy in Fmr1 KO 
mice. The binding levels of both BRD2 and BRD3 at the cis-regulatory 
regions were significantly lowered in Fmr1 KO mice, but BRD4 re-
cruitment level was largely unchanged except at the BRD4-bound 
enhancers where BRD4 binding was marginally increased (Fig. 7, 
C to E, and fig. S8, C and D). These results could be confounded by 
heterogeneous cell types present in the brain, potentially masking 
the specific effects of Fmr1 KO in neurons. To clarify this issue, 
we also analyzed fluorescence-activated cell sorting (FACS)–sorted 
neuronal nuclei from the cortices and observed the same effect 
of Fmr1 KO in the expression of individual BET family proteins 
(fig. S8E).
To examine whether the decrease in the chromatin occupancy of 
BRD2 and BRD3 also contributes to the abnormalities of FXS, we 
analyzed mRNA-seq data generated from Fmr1 KO neurons (37). 
FMRP deficiency induces up- and down-regulation of many genes 
(KO-regulated genes; FC > 1.2) with a trend toward more signifi-
cant down-regulation (Fig.  7F). We compared this gene list with 
BET protein–regulated genes in two categories that required BET 
protein function, KCl-up and JQ1-down genes identified from our 
mRNA-seq in the same neuronal culture. The KCl-up genes that 
were also present in the KO-regulated group largely showed a de-
crease in transcription in Fmr1 KO neurons (Fig. 7, F to H). Likewise, 
transcription levels of the JQ1-down genes were mostly decreased 
in Fmr1 KO. The chromatin occupancy of BRD2 and BRD3, but not 
BRD4, was also significantly decreased at the promoters of the genes 
in these two groups (Fig. 7I). Although the comparison between the 
chromatin occupancy changes and DEGs was made with the data 
obtained from different experimental conditions (primary neuronal 
culture for DEG and P60 cortex tissue for ChIP-seq), these results 
are consistent with the model that perturbation of the BET protein 
recruitment might contribute to the transcriptional abnormality in 
FXS. We also examined the changes in peak intensity at the cis- 
regulatory regions of the KO-regulated genes to see whether there 
was a direct correlation between the BET chromatin occupancy and 
transcriptional changes in Fmr1 KO (Fig. 7, J and K). Both BRD2 
and BRD3 showed decreased binding at the promoters of KO–
down-regulated (KO-down) genes but not at the KO–up-regulated 
(KO-up) genes. There was no change in BRD4 binding levels in either 
group. In the case of the BET-bound enhancers located within the 
±50 kb from the KO-regulated genes, we observed decreased BRD2 
binding at the enhancers associated with the KO-down genes 
(Fig. 7K). The enhancers associated with KO-up genes showed in-
creased binding of all BET family members, especially BRD2 and 
BRD3. However, the fractions of KO-regulated genes that are di-
rectly bound by BET proteins (BET-bound KO-regulated genes) are 
quite small (Fig. 7J), indicating that the majority of transcriptional 
changes in Fmr1 KO result from either indirect effects or posttran-
scriptional mechanisms. This is consistent with the well-established 
role of FMRP in translational control. As FXS is a neurodevelop-
mental disorder with deficits emerging early in development, it is 
also possible that the causative molecular changes could have oc-
curred earlier than the age we investigated (P60). For example, P20 
mice showed changes in all three BET family members (BRD2/3 
down and BRD4 up) (Fig. 7A). It is possible that alterations in the 
expression of all three BET families collectively contribute to the 
FXS phenotypes. The KO-regulated gene group contains a number 
of histone modifiers and remodelers, which could collectively alter 
the chromatin landscape in Fmr1 KO mice and influence BET re-
cruitment (fig. S8F). Together, our analysis of the KO-regulated genes 
that are directly bound and regulated by BET proteins demonstrates 
that perturbation of the BET protein recruitment contributes to the 
transcriptional abnormality in FXS. Our study further implicates 
that JQ1 might not be an optimal solution for rescuing FXS, as the 
recruitment of individual BET family proteins is differentially al-
tered in Fmr1 KO mice.
Inhibition of CBP/p300 HAT activity could reverse altered 
BET binding and rescue memory deficit of Fmr1 KO mice
CBP/p300 HAT activity was known to be important for the 
bromodomain-dependent BRD4 recruitment to the chromatin (20). 
Having observed a range of JQ1 sensitivity in neurons, we next ex-
amined the role of CBP/p300 in the chromatin binding of individual 
BET family proteins. CBP/p300 HAT activity provides the substrates 
for BET protein binding by acetylating the lysine residues present at 
the histone tails as well as nonhistone proteins. We initially thought 
that BRD2 might critically rely on CBP/p300 HAT activity due to 
more prominent bimodal enrichment patterns flanking the TSSs 
that coincide with positioned nucleosomes and a higher sensitivity 
to JQ1 than the other BET family members. Unexpectedly, an acute 
inhibition of CBP/p300 HAT activity by a specific inhibitor C646 
(20 M) enhanced BRD2 recruitment to the cis-regulatory regions 
(Fig. 8, A and C to E, and fig. S9, A to D). No change was observed in 
BRD3 binding, and BRD4 was the only BET family member that 
showed decreased binding by C646. Increased BRD2 binding oc-
curred at the regions where BRD4 binding levels were decreased, 
suggesting that loss of BRD4 binding was compensated by BRD2 
(Fig. 8, F and G, and fig. S9E). This result illustrates that BET family 
members functionally coordinate with each other rather than sim-
ply acting in a redundant manner. Besides its HAT activity, CBP/
p300 also functions as a coactivator to mediate protein-protein in-
teractions with various types of transcriptional regulators. To see 
whether BET proteins require CBP/p300 coactivator function for 
their recruitment, we also performed CBP KD (Fig. 8B). In this case, 
all BET proteins showed decreased binding levels at the promoters 
and the enhancers, suggesting that a physical association with CBP 
also played a role in the BET recruitment to the cis-regulatory re-
gions (Fig. 8, C to E, and fig. S9, A to D). Considering the average 
binding peak of BRD3 present within the NFRs as well as its insen-
sitivity to JQ1 (Fig. 2, E and F, and fig. S4A), it might be that BRD3 
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Fig. 7. Expression and recruitment of BET proteins to the cis-regulatory regions are differentially altered in Fmr1 KO. (A) Western blotting data showing represent-
ative expression data of BET and FMRP proteins in WT and KO cortices at P0, P20, or P60 that was from biological replicates (n = 2, 4, or 4). (B) The quantified average band 
intensities of three gradient lanes in each WT or KO in (A) using ImageJ were used for the graph presentation. Bar graphs show means ± SEM. (P values were from two-
tailed unpaired t test with Welch’s correction). (C) ChIP-seq read densities of BET proteins in different categories at the cis-regulatory regions. (D and E) Representative 
ChIP-seq tracks at the Nr4a1 and Arc gene loci. (F) Violin plots showing the RPKM-FC (log2) distributions of different categories of genes overlapped with KO-regulated 
genes. (P values were from Mann-Whitney U test). (G) The RPKM-FC (log2) in (F) are ranked in increasing order. (H) Venn diagram showing the overlap among different 
categories of genes. (P values were from hypergeometric tests). (I) ChIP-seq read densities of BET proteins around the TSSs of genes in different categories. (J) ChIP-seq 
read densities of BET proteins around the TSSs of KO-regulated genes in different categories. (K) ChIP-seq read densities of BET proteins centered on enhancers associated 
with BET-bound KO-regulated genes.
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Fig. 8. CBP/p300 HAT activity differentially affects BET protein recruitment, and its inhibition rescues the memory deficit of Fmr1 KO. (A) Effect of CBP/p300 HAT 
inhibition by C646 in H3K27ac level in neurons. Quiescent neurons in TTX were added with C646, followed by KCl depolarization, and then subject to Western blotting. 
(B) The efficiency of lentivirus-mediated CBP KD. (C) Representative ChIP-seq tracks showing the Fosl2 gene locus. C646 (20 M) were treated for 48 hours. (D) ChIP-seq 
read densities of BET proteins around the TSSs of KCl-up/JQ1-down genes in two different paired conditions. (E) ChIP-seq read densities of BET proteins centered on 
BRD2/3/4-cobound SEs or TEs. (F) ChIP-seq read densities of BET proteins aligned at the centers of increased (BRD2-up) and decreased (BRD4-down) peaks by C646. 
(G) Heatmaps showing the intensities of BRD2-up and BRD4-down peaks in different conditions. (H) Effect of C646 injection in Fmr1 KO mice. Whole-cell extracts from WT 
littermate and KO cortical tissues given vehicle or C646 (15 mg/kg) through intraperitoneal injection for 2 days were analyzed by Western blotting using the antibodies 
indicated on the right. (I) Scheme of experiment designs. (J and K) Effect of C646 in fear memory. WT or KO mice were given vehicle or C646 through intraperitoneal 
injection for 2 days (n = 5 each). P values were determined by two-tailed paired t test.
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is primarily recruited to their target loci through protein-protein 
interactions with CBP/p300 and other factors (Fig. 5G).
We noted that the altered binding patterns of BRD2 and BRD4 
caused by C646 was opposite to those in Fmr1 KO mice, which 
raised a possibility that CBP/p300 HAT inhibition by C646 might 
be able to alleviate the abnormality of Fmr1 KO. Although C646 is 
not expected to reverse the abnormal decrease in BRD3 binding at 
the cis-regulatory regions, the contribution of BRD3 to gene expres-
sion and memory behavior was minimal in our analysis. C646 treat-
ment for 48 hours substantially reduced the levels of H3K27ac and 
H4K8ac in both WT and Fmr1 KO mice at P60, suggesting that 
these lysine residues are subject to CBP/P300-dependent acetyla-
tion (Fig. 8H and fig. S9F). Using this condition, we compared the 
effects of C646  in long-term fear memory between WT and KO 
mice. While C646-mediated inhibition of CBP/p300 HAT activity 
impaired LTM formation of WT, the memory deficit caused by 
Fmr1 KO was effectively rescued to the degree shown by WT with-
out any treatment (Fig. 8, I to K, and fig. S9, G and H). This result 
supports our conclusion that altered BET coordination could un-
derlie the pathogenesis of FXS.
DISCUSSION
BET family proteins have been studied in a wide range of cell types 
and diseases as key epigenetic regulators that control gene expres-
sion, and small-molecule inhibition of their bromodomains is rec-
ognized as an effective treatment option. Understanding the precise 
molecular mechanism of BET inhibition in diverse cellular contexts 
would be highly valuable not only for advancing our knowledge in 
epigenetic regulation but also for developing the treatment option 
suitable for each disease type. Our study demonstrated that individ-
ual BET proteins are recruited to the cis-regulatory regions with a 
hierarchical coordination. The chromatin binding profile in re-
sponse to the inhibition of the BET bromodomain and CBP/p300 
HAT activity was widely varied among the family members, sug-
gesting that the recruitment of each BET family member was medi-
ated by distinctive mechanisms. Our study with a mouse model of 
FXS further demonstrated that perturbation of BET protein coordi-
nation is, in part, responsible for altered transcription and resulting 
in the pathological conditions manifested by Fmr1 KO.
Most BET inhibition studies attribute the effects of small-molecule 
inhibitors to dysregulation of BRD4 function, despite that cur-
rently available BET inhibitors exhibit similar affinities to the bromo-
domains present in all family members in vitro. Such a notion is due 
to either lack of studies with all major BET family proteins or, in 
some cases, the effects of pharmacologic BET inhibition were suffi-
ciently recapitulated by BRD4 single KD (33). We confirmed that 
the three major BET family members, BRD2, BRD3, and BRD4, are 
quite ubiquitously expressed in the brain even at a single-cell level 
(fig. S2A and table S2) and, therefore, wondered whether JQ1 would 
affect all major family members equally or differentially in vivo. Al-
though BET proteins extensively co-occupied the cis-regulatory re-
gions, each BET protein differentially responded to JQ1 treatment 
in neurons with BRD2 being the most sensitive member (Figs.  2 
and 3). To our surprise, BRD4 was marginally affected by short-term 
JQ1. The average occupancy peak of BRD2 near the TSS coincides 
with positioned nucleosomes flanking the cis-regulatory regions, 
whereas BRD3 and BRD4 were more enriched within the NFR. Such 
binding profiles could be relevant to the observed differential JQ1 
sensitivity such that BRD2 primarily relies on acetylated histones 
for its recruitment to the cis-regulatory regions, which is effectively 
disrupted by JQ1. The interaction with various TFs located at the 
NFRs might be a preferential mechanism used by BRD3 and BRD4 
with a varying degree of dependence on acetylation. The ET domain 
commonly present in BET family proteins could be an important 
player for this type of interactions to confer a binding specificity 
(8, 32, 44). Together, these results demonstrate that BET family 
members are recruited to their common target genes by distinctive 
mechanisms.
Our experimental system permitted an investigation of the coor-
dination between the family members by monitoring BET recruit-
ment and the effect of BET inhibition during the initial stage of 
transcriptional induction. Stimulus-induced gene expression occurs 
in a transcriptional wave over time (45). Rapid induction of IEGs by 
sensory stimulation is the first step in the transcriptional cascade, 
which has been shown to be critical for gene expression–dependent 
neuronal plasticity. We applied JQ1 to primary cultures of mouse 
cortical neurons 5 min before KCl-mediated gene induction. Like-
wise, our in vivo experiments were performed with an acute BET 
inhibition in which JQ1 was injected only 15 min before fear condi-
tioning. Acute BET inhibition might have affected relatively a small 
number of genes, but it should help reveal a direct effect of BET 
inhibition without having secondary effects caused by a long-term 
inhibition. Our findings from the analysis of recruitment kinetics 
and protein-protein interactions (Figs. 3 and 4) suggest a model 
where BRD2/3 work together in the early stage of the transcriptional 
process such as promoter remodeling and initiation, whereas BRD4 
primarily functions in a later stage such as transcription elongation 
(fig. S10). We also noted that a substantial fraction of BRD3 remains 
bound to the cis-regulatory regions even after a long period of activ-
ity suppression (Fig. 4), suggesting a possibility of a unique BRD3 
function in gene repression. Our model integrates the coordination 
of all major BET proteins during transcriptional activation, which is 
consistent with previously reported features of individual family mem-
bers. For example, BRD4 was shown to control transcriptional elonga-
tion by interacting with Mediator and P-TEFb (1, 6, 8, 13, 46). BRD2 
was shown to be present in the complex with Pol II and TBP-associated 
factors, HATs CBP/p300, and chromatin assembly and remodeling fac-
tors (29, 42). BRD3 is recruited by GATA binding protein 1 (GATA1) 
to both active and repressed genes in erythroblast (47).
An intriguing feature of BET inhibition is that, despite the wide-
spread chromatin binding of BET proteins across a large number of 
genes and regulatory regions, only a selective gene set is affected by 
BET inhibition, which often occurs in a context or cell type–specific 
manner (3, 4). Such selective effects of BET inhibition have been 
ascribed to the fact that BET proteins at enhancers are more sensi-
tive to BET inhibitors (9, 27). In particular, BET proteins bound at 
SEs were shown to be more sensitive to BET inhibition than TEs, 
leading to alteration of SE-regulated gene expression (9). Our study 
also found that BET proteins at enhancers were more vulnerable to 
JQ1 than those at promoters despite that promoters and coding re-
gions take up the largest fraction of BET-binding peaks. However, 
there was no difference in JQ1 sensitivity between BRD2/3/4-cobound 
SEs and TEs, and only a small number of JQ1–down-regulated genes 
are regulated by BET-bound SEs (Fig. 3, C and E). This indicates 
that BET disruption at the SE cannot be the major determinant for 
the JQ1 sensitivity in neurons. Genes (39.33%) whose transcription 
was down-regulated by JQ1 had BET binding only at promoters 
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(Fig. 3G). Thus, the molecular mechanism of BET protein action 
could be cell context dependent. The local environment of a gene is 
also an important determinant for BET sensitivity, as reduced BET 
binding, especially BRD2, also occurs beyond the cis-regulatory re-
gions of JQ1-down genes. Noted from our peak analysis was that 
BRD2/3/4-cobound regions were more effectively disrupted by JQ1 
than the regions bound by one or two family members (Fig. 2E and 
fig. S4A). Although further studies will be needed to understand the 
exact nature of the cellular and gene context that determines the 
sensitivity to BET inhibition, our observation suggests that a coor-
dinated nature of BET proteins underlies differential JQ1 sensitivity.
Recent studies in the brain reported that BET function is im-
portant for neuronal gene expression and behavior, but the benefi-
cial effects of BET inhibition were somewhat inconclusive. For 
example, one study found that BET inhibition by I-BET858 in WT 
caused the development of autism-like syndromes, but other study 
showed that JQ1 improved memory performance of WT mice and 
also ameliorated autism phenotypes when treated in the FXS mouse 
model (35, 37). BET inhibition in neurodegenerative disorders also 
showed mixed results (36, 38, 39). These mixed effects of BET inhi-
bition could be accounted for by the experimental conditions such 
as the dose, duration, and the type of inhibitor used in each study 
but also implicate that nonspecific BET inhibition might have side 
effects. Our study attempted to understand the molecular nature of 
BET inhibition in more detail by investigating all three major BET 
family members in an FXS mouse model. We saw increased expres-
sion of BRD4 protein in Fmr1 KO mice in P20 mice as reported in a 
previous study (37), but at P60, we found that the chromatin bind-
ing level of BRD4 was largely unaffected across the cis-regulatory 
regions except at a small number of enhancers (Fig. 7C). Unexpect-
edly, we saw concomitant decreases in BRD2/3 expression in Fmr1 
KO, which also caused a significant impairment in their chromatin 
binding. Altered bindings of individual BET proteins were largely 
correlated with transcriptional changes. Therefore, FXS phenotypes 
result from the combined consequences from the functional alter-
ations of BRD2/3 and BRD4 in the opposite direction. According to 
this finding, BET inhibition alone would not be an optimal solution 
for treating FXS syndrome as it could exacerbate the impairment in 
BRD2/3 function while abnormally activated enhancers caused by 
additional BRD4 binding might be suppressed. Our finding of an 
unexpected relationship between CBP/p300 HAT activity has of-
fered an alternative strategy for alleviating the FXS. Although HAT 
activity has mainly been linked to enhanced LTP (48) and memory 
formation (49), our study has revealed an unexpected relationship 
between CBP/p300 HAT activity and BET recruitment. Although 
CBP/p300 activity was known to be important for the bromodomain- 
dependent recruitment of BET proteins (20), we found that individ-
ual family members were differentially affected by the CBP/p300 
small-molecule inhibitor, C646. C646-induced alterations in BET 
occupancy showed the opposite trend with the BET binding pat-
terns observed in Fmr1 KO mice except for BRD3 that showed no 
or little change (Figs. 6D and 7D). Given that BRD3 had a minimal 
impact on gene expression and behavior (Figs. 1J and 5D), restoring 
the occupancy patterns of BRD2 and BRD4 in FXS by C646 might 
be able to ameliorate the FXS syndromes. We found that the treat-
ment of Fmr1 KO mice with C646 significantly improved fear mem-
ory formation (Fig. 8, H to K). Our study also provides a molecular 
mechanism for the previous observation that CBP/p300 HAT inhi-
bition could have a positive impact on neuronal plasticity and 
memory formation (50, 51). Together, our findings of the coordi-
nated interplay between BET family members have uncovered de-
tailed molecular features of BET inhibition, providing previously 
unknown insight into the development of BET regulation–based 
therapeutic approach. Our study also suggests that the development 
of additional BET inhibitors that are specific for each family mem-
ber would offer improved treatment options.
MATERIALS AND METHODS
Animals
All experiments carried out using animals were reviewed and approved 
by the Institutional Animal Care and Use Committee at University 
of Texas Southwestern Medical Center and Pohang University of 
Science and Technology. Congenic Fmr1 KO mice were provided by 
K. M. Huber and bred on the C57BL/6J background.
Mouse cortical neuron culture and stimulation
Mouse cortical neurons were dissected at embryonic day 16.5 (E16.5) 
and cultured in neurobasal media (NB) (Thermo Fisher Scientific, 
21103) supplemented with 2% B-27 (Thermo Fisher Scientific, 17504) 
and 1% GlutaMAX (Thermo Fisher Scientific, 35050). For KCl de-
polarization, neurons at days in vitro (DIV) 7 were made quiescent 
by 1 M TTX (Tocris, Minneapolis, MN; 1078) overnight and then 
added with 55 mM KCl for the indicated length of time. In BDNF 
stimulation experiment, neurons without TTX treatment were in-
cubated with BDNF (10 ng/ml; R&D System, Minneapolis, MN; 248-
BD-005) for the indicated length of time. For JQ1 experiment, 
TTX-treated neurons at DIV 7 were pretreated with ±JQ1 (0.5 M; 
ApexBio Technology, Boston, MA; A8181/A1910) for 5  min and 
then followed by 55 mM KCl for the indicated length of time. For 
C646 experiment, quiescent neurons were pretreated with C646 
(20 M; Sigma-Aldrich, St. Louis, MO; SML0002) for 48 hours, fol-
lowed by 55 mM KCl for 30 min.
shRNA design, transfection, and lentivirus infections
shRNAs against Brd2, Brd3, Brd4, and Cbp were designed as de-
scribed (52, 53). Individual shRNAs were subcloned into the Hpa I/
Xho I sites of the pLLX lentiviral vector. To generate lentivirus, lenti-
viral constructs containing the indicated shRNAs in the pLLX-
shRNA-GFP, along with the helper plasmids 8.9 and vesicular 
stomatitis virus (VSV-G), were cotransfected into human embryonic 
kidney (HEK) 293T cells using polyethylenimine (PEI; 1 mg/ml; 
Polysciences, Warrington, PA; 23966). NB supplemented with B-27 
and GlutaMAX was completely changed on the next day. Lentivirus 
transduction was carried out for additional 48 to 72 hours. Lentivirus 
containing media was filtered by a syringe filter (0.45 m; Millipore, 
SLHV033RS) and directly used to infect neurons at DIV 3 and har-
vested at DIV 7. KD efficiency was measured by RT-qPCR and 
Western blotting. See table S6 for complete oligonucleotide list.
Real-time quantitative polymerase chain reaction
Total RNA was prepared from cortical neurons at DIV 7 using 
TRIzol (Invitrogen, Carlsbad, CA; 15596) according to the manu-
facturer’s protocols. Subsequently, total RNAs were reverse tran-
scribed into cDNA using high-capacity reverse transcription kit 
(Applied Biosystems, Warrington, UK; 4374967). Primers used are 
listed in table S6. PCR amplification conditions were previously 
described (54).
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Chromatin immunoprecipitation
ChIP assays were carried out as previously described with minor 
modifications (54). At DIV 7, cultured cortical neurons were treated 
with the indicated conditions and then fixed in cross-linking buffer 
[0.1 M NaCl, 1 mM EDTA, 0.5 mM EGTA, and 25 mM Hepes-KOH 
(pH 8.0)] containing 1% formaldehyde (Sigma-Aldrich, 252549) for 
10 min at room temperature. Cross-linking was quenched by gly-
cine (final 125 mM) for 5 min at room temperature and harvested 
in phosphate-buffered saline protease inhibitors on ice. Pelleted 
neurons were lysed in ice-cold buffer I [50 mM Hepes-KOH 
(pH 7.5), 140 mM NaCl, 1 mM EDTA (pH 8.0), 10% glycerol, and 0.5% 
IGEPAL CA630 and protease inhibitors] to isolate nuclei. Nuclei 
were sonicated in ice-cold buffer III [10 mM tris-HCl (pH 8.0), 300 mM 
NaCl, 0.1% sodium deoxycholate, 1% Triton X-100, 1 mM EDTA 
(pH 8.0), 0.5 mM EGTA (pH 8.0), and protease inhibitors]. The 
resulting nuclear extracts were centrifuged at 13,200 rpm for 15 min 
at 4°C to separate insoluble fraction. The supernatant was then in-
cubated with anti-BRD2 (Bethyl, A302-583A), anti-BRD3 (Active 
Motif, 61489), or anti-BRD4 (Bethyl, A301-985A100 or rabbit anti-
body gifted by C.-M. Chiang) overnight at 4°C. The immune com-
plexes were pelleted and washed twice with each of the following 
buffers: low salt [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
tris-HCl (pH 8.1), and 150 mM NaCl], high salt [0.1% SDS, 1% Tri-
ton X-100, 2 mM EDTA, 20 mM tris-HCl (pH 8.1), and 500 mM 
NaCl], and LiCl buffer [250 mM LiCl, 1% IGEPAL CA630, 1% sodi-
um deoxycholate, 1 mM EDTA, and 10 mM tris (pH 8.1)]. In each 
wash, the beads were incubated with wash buffer for 10  min at 
4°C. The washed beads were then rinsed once with 1× TE [10 mM 
tris-HCl (pH 8.0) and 1 mM EDTA]. The immune complexes were 
eluted from the beads twice by elution buffer [10 mM tris-HCl 
(pH 8.0), 1 mM EDTA (pH 8.0), and 1% SDS] at 65°C for 10 min. 
The cross-linking was reversed by incubation at 65°C for 5 to 6 hours. 
The resulting eluate was treated with RNase A (10 g; Qiagen, 
Hilden, Germany) for 1 hour at 37°C and proteinase K [4 U; New 
England Biolabs (NEB), Ipswich, MA; P8107S] for another 2 hours 
at 55°C. The DNA was purified by phenol:chloroform extraction 
(Thermo Fisher Scientific, 15593), followed by a PCR purification 
kit (Qiagen, Hilden, Germany; 28106). Primers are listed in table S6.
ChIP sequencing
ChIP-seq library construction was performed using NEBNext 
ChIP- Seq Library Prep Master Mix Set (NEB, E6240) following the 
manufacturer’s instruction with modifications. Briefly, the end- 
repaired ChIP DNA fragments were size selected [100 to 300 base 
pairs (bp)], deoxyadenosine triphosphate (dATP) [dA] tailed, and 
then ligated with adaptors. The adaptor- ligated ChIP DNA fragments 
were digested by USER enzyme and amplified by 14 to 16 cycles of 
PCR. The amplified ChIP DNA library was size selected (250 to 350 bp) 
and proceeded to sequencing.
ChIP-seq libraries were sequenced on Illumina HiSeq 2500 or 
NextSeq 500 instrument with 50- or 75-bp single-end reads accord-
ing to the manufacturer’s instructions (Illumina) by the UTSW 
McDermott Next Generation Sequencing Core. The FASTQ reads 
were aligned to UCSC’s mm10 genome using Bowtie2 with default 
parameters (55). Reads with mapping quality of less than 10 were 
removed using SAMtools (56). To normalize the differences in se-
quencing depths, the mapped reads were “down sampled” to the 
lowest number of the uniquely mapped reads with duplicates followed 
by duplicate reads removal using “Sambamba” (57). The bigWig files 
were generated using “bamCoverage” included in the “deepTools” 
package for visualization on University of California Santa Cruz 
(UCSC) genome browser. The coverage values in bigWig files were 
normalized to RPGC (reads per genomic content).
ChIP peaks were called using model-based analysis of ChIP-
Seq (MACS) with parameters “--tsize=50 --gsize mm --nomodel 
True --shiftsize=65 --wig --space=10” against input chromatin sam-
ples as control data (58). Threshold for P value was set at 1 × 10−9. 
Threshold for the fold_enrichment was set at 10. Master peaks (or 
reproducible peaks) were identified only if the ChIP-seq peaks overlap 
more than 50% of the shortest peaks in −JQ1 samples across two 
replicates. To find overlapping peaks among different BET proteins 
and to call the differentially bound peaks under different conditions, 
we merged the master peaks from different samples, called “merged 
peaks”. Mergepeaks of Hypergeometric Optimization of Motif 
EnRichment (HOMER) (59) was used.
To generate ChIP coverage plots, we used either Ngs.plot R pack-
age (60) or HOMER. For the ngs.plot software, the parameter of 
Fragment (insert) length was set to 180, and Refseq database mm10 
was used. For HOMER, “makeTagDirectory” program was used. We 
used BAM files that contained down-sampled duplicate removed 
reads to create tag directories, which contain tag information classi-
fied per chromosome wise. Using HOMER’s inbuilt Perl scripts 
annotatePeaks.pl and analyzeRepeats.pl, data were used to create 
coverage plots.
Identification of SEs and TEs
SEs and TEs were identified according to MACS-called H3K27ac- 
enriched peaks. First, H3K27ac peaks were identified in p56 tissue 
(GSM1264366-GSM1264369) (61) and KCl-stimulated neurons 
(GSM1467414-GSM1467419) (62) using MACS (58). Mapped reads 
of two biological replicates in each condition group were merged 
before the SE calling analysis using Bamtools (63). Then, the rank-
ing of super-enhancer (ROSE) algorithm (9) was used to define SEs 
with the identified H3K27ac peaks. A line with a slope of one tan-
gent to the curve is used as a cutoff to distinguish SEs above the 
point and TEs below the point of tangency. SEs are defined as the 
population of enhancers above the inflection point of the curve. 
The H3K27ac peaks that were not overlapped with the SE or promoter 
regions of known genes were defined as TEs. SE- or TE-regulated 
genes were defined as genes within 50 kb upstream and downstream 
of SEs or TEs. SE- or TE-based scaled plots were generated using 
deepTools (64).
mRNA sequencing
mRNA-seq library was constructed using the TruSeq RNA Library 
Preparation Kit (Illumina) according to the manufacturer’s instruc-
tions. FASTQ reads from UTSW Sequencing Core were mapped to 
UCSC’s mm10 genome using TopHat (65) with options “-a 8 -m 
0 -I 500000 -p 8 -g 20 --library-type fr-firststrand --no-novel- 
indels --segment-mismatches 2”. Since these data were strand specif-
ic, we used “-library-type fr-firststrand” option from TopHat. Reads 
with low mapping quality (<10) were removed using SAMtools (56). 
Duplicate reads were marked by Picard MarkDuplicates (https://
broadinstitute.github.io/picard/). Tag directories for each sample 
were created using the “makeTagDirectory” program. RNA expression 
was quantified using HOMER’s inbuilt Perl script “analyzeRepeats.pl.” 
These scripts offer flexibility to calculate expression values as reads 
per kilobase per million mapped reads (RPKM) normalized to 10 million 
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at introns, exons, and gene body locations. “makeUCSCfile” from 
HOMER was used to create bedGraph files at 1-bp resolution and 
created bigWig files for visualization on UCSC genome browser. All 
coverage values were normalized to 10 million reads.
We set expressed gene criteria as “RPKM values higher than 1 at 
least in 1 of 12 JQ1-related samples (six conditions, two replicates 
for each condition).” We identified 12,723 “expressed” genes. The 
subsequent RNA-seq analyses were performed with these 12,723 
genes. To call significant DEGs, we set our criteria as “FC of RPKM 
is more than 1.5 and FDR of DESeq2 is less than 0.05 in both repli-
cates.” To identify +JQ1 or KCl-dependent genes, we took genes 
that were significantly changed at either time point (1 or 3 hours).
Global run-on sequencing
Ten million nuclei per sample were used for global run-on, and base 
hydrolysis was performed as previously described (66). Nascent RNA 
was immunoprecipitated with anti-BrdU antibody-conjugated beads 
(Santa Cruz Biotech, Santa Cruz, CA; sc-32323AC). Purified run-
on RNA was subjected to polyA tailing by poly(A)polymerase 
(14.06 U; NEB, M0276) for 12 min at 37°C. PolyA-tailed RNA was 
subjected to another round of immunopurification by using anti- 
BrdU antibody-conjugated beads. Reverse transcription was then 
performed using SuperScript III Reverse Transcriptase (200 U; 
Thermo Fisher Scientific, 18080) with RT primer (pGATCGTCG-
GACTGTAGAACTCT/idSp/CCTTGGCACCCGAGAATTC-
CATTTTTTTTTTTTTTTTTTTTVN) for 2 hours at 48°C. Extra 
RT primers were removed by Exonuclease I (100 U; NEB, M0293) 
for 2 hours at 37°C. cDNAs were fragmented with basic hydrolysis 
and size selected (130 to 500 nucleotides) in a 6 to 8% polyacryl-
amide tris-borate-EDTA (TBE)–urea gel. Purified cDNAs were cir-
cularized using CircLigase (50 U; Epicentre, CL4111K) for 2 hours 
at 60°C and relinearized at the basic dSpacer furan with Ape 1 (15 U; 
NEB, M0282) for 2 hours at 37°C. The relinearized single-stranded 
DNA template was subjected to PCR amplification by using bar-
coded primers for Illumina TrueSeq small RNA sample and Phusion 
High-Fidelity DNA Polymerase (2 U; NEB, M0530). Subsequently, 
PCR products were size-selected in 6% polyacrylamide TBE gel 
(175 to 400 bp) and purified. The final libraries were sequenced using 
Illumina NextSeq 500 per the manufacturer’s instructions.
For analysis, the raw FASTQ reads were trimmed using cutadapt 
with parameters -a AAAAAAAAAAAAAAAAAAAA -z -e 0.10 -f 
fastq -m 32 (67). The reads were then submitted to Burrows-Wheeler 
aligner (BWA) for mapping to the mm10 UCSC annotation. SAMtools 
and the HOMER package were used to make visualization tracks and 
RPKM calculations. RPKM was calculated by normalizing to 10 million 
reads. We set expressed gene criteria as “RPKM is more than 0.5 at 
least in 1 of 20 samples (10 conditions, two replicates for each con-
dition).” We identified 12,974 expressed genes. The subsequent GRO- 
seq analyses were done with these 12,974 genes. To call significant 
DEGs, we set our criteria as “fold change of RPKM is more than 1.5 
and FDR of DESeq2 (68) is less than 0.05 in both replicates.” See 
table S3 for DEGs.
Rapid immunoprecipitation mass spectrometry 
of endogenous proteins
RIME was performed as previously described (41) except that corti-
cal neurons at DIV 7 were subject to the ChIP procedure described 
above. Precipitated protein complexes were boiled for 10 min in SDS 
sample buffer and separated by SDS–polyacrylamide gel electrophoresis 
(PAGE). Gel bands were digested overnight with trypsin (Pierce), 
followed by destaining, reduction with dithiothreitol, and alkylation 
with iodoacetamide (Sigma-Aldrich). The samples then underwent 
solid-phase extraction cleanup with an Oasis HLB plate (Waters), 
and the resulting samples were injected onto an Orbitrap Fusion 
Lumos mass spectrometer coupled to an Ultimate 3000 RSLCnano 
liquid chromatography system. Samples were injected onto a 75-
m i.d., 75-cm long EasySpray column (Thermo Fisher Scientific) 
and eluted with a gradient from 0 to 28% buffer B over 90 min. Buf-
fer A contained 2% (v/v) acetonitrile (ACN) and 0.1% formic acid 
in water, and buffer B contained 80% (v/v) ACN, 10% (v/v) trifluo-
roethanol, and 0.1% formic acid in water. The mass spectrometer 
operated in positive ion mode with a source voltage of 1.8 kV 
and an ion transfer tube temperature of 275°C. MS scans were ac-
quired at 120,000 resolution in the Orbitrap, and up to 10 tan-
dem MS (MS/MS) spectra were obtained in the ion trap for each full 
spectrum acquired using higher-energy collisional dissociation for 
ions with charges 2 to 7. Dynamic exclusion was set for 20 s after an 
ion was selected for fragmentation.
Raw MS data files were analyzed using Proteome Discoverer 
v2.2 (Thermo Fisher Scientific), with peptide identification using 
Sequest HT searching against the mouse protein database from 
UniProt. Fragment and precursor tolerances of 10 parts per million 
and 0.6 Da were specified, and three missed cleavages were allowed. 
Carbamidomethylation of Cys was set as a fixed modification, with 
oxidation of Met set as a variable modification. Five percent of FDR 
cutoff was used to determine enriched polypeptides. Immunoglobulin 
G IP control was used to exclude nonspecifically associated poly-
peptides. PSMs indicate the number of peptide spectrum matches 
or the number of spectra assigned to peptides that contributed to 
the inference of the protein. Abundance indicates the sum of the 
peak intensities for each peptide identified for that protein.
Western blot
Protein extracts from cortical neurons or tissues were prepared with 
sample buffer [60 mM tris-HCl (pH 6.8], 2% sodium dodecyl sul-
fate, 10% glycerol, 5% 2-mercaptoethanol, and 0.1% bromophenol 
blue] and boiled for 5 min. For FACS sorting, the whole cortex dis-
sected from WT or Fmr1 KO was homogenized by douncing fol-
lowed by nuclei extraction via sucrose gradient ultracentrifugation 
(69). The nuclei were recovered from the pellet, resuspended, and 
incubated with NeuN antibody (Millipore, MAB377). Immunotagging 
with anti-NeuN conjugated to Alexa Fluor 488 (Invitrogen, A-21202) 
allows for sorting of the NeuN+ neuronal nuclei by fluorescence- 
activated sorting through a FACS machine (MoFlo Astrios, Beckman 
Coulter), followed by Western blotting. Proteins were separated by 
SDS-PAGE and subjected to Western analysis using the following 
antibodies: anti-BRD2 (Bethyl, A302-583A), anti-BRD3 (Active 
Motif, 61489) or anti-BRD4 (Bethyl, A301-985A100), anti-CBP (Santa 
Cruz, sc-369x), anti-FMRP (Cell Signaling, 4317S), anti–-actin 
(Santa Cruz, sc-47778), anti–-tubulin (Cell Signaling, 2144S), anti- 
H3K27ac (Abcam, Ab4729), anti-H4K8ac (Abcam, Ab15823), 
anti-H3K4me1 (Abcam, Ab8895), anti-H3ac (Millipore, 06-599), 
or anti-H3 (Abcam, ab176842).
Immunoprecipitation analysis
IP analysis was performed as previously published (52) with minor 
modifications. Cortical neurons at DIV 6 to 7 were made quiescent 
overnight in 1 M TTX and then KCl (55 mM) depolarized for 
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30 min. Neurons were lysed in ice-cold lysis buffer [50 mM Hepes-
KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA (pH 8.0), 10% glycerol, 
and 0.5% IGEPAL CA630 and protease inhibitors]. Nuclei were pel-
leted by centrifugation at 3000 rpm for 5 min at 4°C and then added 
with ice-cold extraction buffer [10 mM tris-HCl (pH 8.0), 600 mM 
NaCl, 1.5 mM MgCl2, 0.05% sodium deoxycholate, 0.5% Triton 
X-100, 1 mM EDTA (pH 8.0), 0.5 mM EGTA (pH 8.0), and protease 
inhibitors]. Nuclear extract was sonicated briefly and incubated for 
10 min on ice. The resulting extract was diluted to a final concentra-
tion of 100 mM NaCl and cleared by centrifugation at 13,200 rpm 
for 15 min at 4°C. The supernatant was incubated with the indicated 
antibodies at 4°C for overnight with rocking and followed by Pro-
tein A/G PLUS Agarose (Santa Cruz, sc-2003) incubation for 2 hours 
at 4°C. The immune complexes were precipitated and washed three 
times with extraction buffer and boiled for 5  min in SDS sample 
buffer. The samples were separated by SDS-PAGE and subjected to 
immunoblot analysis.
AAV and stereotaxic injection
The shRNAs were cloned into the Bam HI/Eco RI sites of the pAAV- 
U6-shRLuc-CMV-ZsGreen vector (Penn Vector Core, P0111). To 
generate AAV, pAAV-U6-CMV-ZsGreen, along with the Helper 
and AAV-DJ plasmids, were transfected into HEK293T cells using 
PEI (1 mg/ml) for 3 days. Virus purification was performed as pre-
viously described with minor modifications (70). Briefly, cells were 
harvested and incubated in the presence of 0.5% sodium deoxycho-
late and benzonase (50 U/ml) (Sigma-Aldrich, E1014) at 37°C for 
1 hour. The virus was purified using an iodixanol step gradient and 
concentrated using an Amicon Ultra centrifugal filter device [100 K 
nominal molecular weight limit (NMWL), Millipore, UFC910008]. 
The genomic titer of each virus was determined by qPCR. Male 
C57BL/6J mice at 8 weeks of age were anesthetized with tribro-
moethanol (200 mg/kg; Sigma-Aldrich, T48402) (53). AAV (0.6 l 
per hemisphere) was bilaterally injected into the dorsal hippocam-
pal CA1 region using a glass pipette with the following coordinates: 
anteroposterior, +1.90 mm; medial lateral, ±1.25 mm; dorsal ventral, 
−1.20 mm. Animals were subjected to fear conditioning 2 weeks after 
stereotaxic injection.
Behavior experiments
Male mice at 8 to 10 weeks of age were housed in light 12 hours: 
dark 12 hours (LD12:12) conditions. Mice were adapted to handling 
and transportation procedures once a day for 3 to 4 days before the 
experiment. On the day of training, mice were transported to the 
behavior room at least 1 hour before the experiment. Vehicle or +JQ1 
(12.5 mg/kg; ApexBio Technology) was administrated intraperitoneally 
15 min before fear conditioning. Vehicle or C646 (15 mg/kg; Sigma- 
Aldrich, SML0002) was administrated (intraperitoneally) 2 days before 
fear conditioning. AAV-injected mice were subjected to fear condition-
ing after 2 weeks. Mice were briefly anesthetized by isoflurane for 
intraperitoneal injection to minimize the stress induced by injection.
For fear conditioning, mice were placed in the fear conditioning 
chamber and allowed to explore for 3 min (acclimation). Mice were 
then received a 2-s shock (0.86 mA) followed by a 1-min pause. This 
was repeated a total of four times, followed by the final 1-min pause. 
Mice were then returned to their home cage. For some experiments, 
mice were euthanized 1 hour after fear conditioning, and brain tis-
sues were taken out for downstream experiments. For the behavior-
al (freezing) test, 24 hours after fear conditioning, the mice were 
placed back into the same chamber, and freezing behavior was 
monitored via video camera and recorded every 10 s for 3 min with 
Freezeframe 4 software.
Statistics
Statistical analysis was performed using two-tailed unpaired t test 
with Welch’s correction or Mann-Whitney U test for comparison 
between two groups of parametric or nonparametric samples. For 
some datasets, two-tailed paired t test was used for comparison be-
tween two groups of parametric samples. Kruskal-Wallis test was 
also used for comparison between unmatched nonparametric data. 
Statistical significance between cumulative probability graphs was 
determined by the Kolmogorov-Smirnov test. Hypergeometric tests 
were performed in DynaVenn (https://ccb-compute.cs.uni-saarland.
de/dynavenn) implemented in Python for analysis of overlaps of 
gene groups. Bar plots show mean values and error bars for bar 
plots are SEM. No statistical methods were used to predetermine 
sample size, but our sample sizes are similar to those generally used 
in the field. Randomization and blinding were not used. Mice were 
used according to their genotype. We considered P < 0.05 to be sta-
tistically significant (*P < 0.05, **P < 0.01, and ***P < 0.001).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/21/eabf7346/DC1
View/request a protocol for this paper from Bio-protocol.
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